Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Omaveloxolone→

Omaveloxolone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1474034-05-3
Molecular formula
C33H44F2N2O3
Molecular weight
554.7 g/mol
Drug class
Nuclear factor erythroid 2-related factor 2 (Nrf2) pathway activatorantioxidant-response modulator
Mechanism of action
Activates the Nrf2 pathway and may suppress pro-inflammatory NF-kB signalling. The precise mechanism by which omaveloxolone improves neurological function in Friedreich ataxia is not fully established; its action is associated with regulation of cellular antioxidant and mitochondrial stress responses.
Indications / reported uses
  • Treatment of Friedreich ataxia in adults and adolescents aged 16 years and older under the US SKYCLARYS indication; clinical benefit should be interpreted within the approved label and long-term monitoring requirements

Sources: US DailyMed — SKYCLARYS (omaveloxolone) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Omaveloxolone Environmental Risk Assessment (ERA) (the Omaveloxolone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.